Please join us for a lively discussion with Patrice Milos, PhD, Barrett Bready '99 MD '03 and Daniel Holmander Esq., with professor Jason Harry as the moderator. Refreshments will be provided.
Barrett Bready, '99 MD '03
Founder and CEO, Nabsys
Adjunct Assistant Professor of Biotechnology - Brown University.
Dr. Bready has served as CEO of Nabsys since 2005. He led the acquisition of GeneSpectrum as well as the execution of the licensing deal with Brown University. Since joining Nabsys, Barrett has been named one of the top "30 under 30" in New England by Mass High Tech: The Journal of New England Technology and one of "25 movers and shakers" in the state of Rhode Island by the magazine Rhode Island Monthly.
Jason Harry, PhD
Associate Professor of the Practice of Engineering
Jason Harry, PhD has 30 years of commercial and academic experience in the medical device field. He is Associate Professor of the Practice in the School of Engineering, Brown University. His teaching focus, at both undergraduate and graduate levels, is technology-based entrepreneurship, innovation management, and engineering. In addition to his academic work, he is active as a business development consultant to early-stage ventures.
Daniel Holmander, Esq.
Counsel and Chairman Adler Pollock & Sheehan P.C
Daniel is a registered patent attorney who has extensive experience in developing and executing strategies for clients’ intellectual property portfolios with a sharply honed focus on furthering their business objectives. Daniel represents a wide range of clients from early stage technology companies to Fortune 500 companies located throughout the United States and Canada
Patrice Milos, PhD
Co-Founder/President and CEO Medley Genomics
Medley Genomics is dedicated to solving important biological questions through our deep understanding of genomic heterogeneity. Genomic heterogeneity complicates our ability to accurately diagnosis and treat complex diseases. New technologies help quantify heterogeneity in biological samples, but lead to analytical challenges in translating this data to clinically actionable knowledge. Our initial focus on cancer—using our novel analytical approaches to describe patient tumor cell sub-populations—supports efforts to improve patient’s outcomes